- Home
- NA vs LPCN Comparison
NA vs LPCN Comparison
Compare NA & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NA
- LPCN
- Stock Information
- Founded
- NA 2019
- LPCN 1997
- Country
- NA China
- LPCN United States
- Employees
- NA N/A
- LPCN N/A
- Industry
- NA Semiconductors
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- NA Technology
- LPCN Health Care
- Exchange
- NA Nasdaq
- LPCN Nasdaq
- Market Cap
- NA 32.3M
- LPCN 36.8M
- IPO Year
- NA 2022
- LPCN N/A
- Fundamental
- Price
- NA $8.76
- LPCN $4.98
- Analyst Decision
- NA
- LPCN Strong Buy
- Analyst Count
- NA 0
- LPCN 1
- Target Price
- NA N/A
- LPCN $10.00
- AVG Volume (30 Days)
- NA 240.6K
- LPCN 30.1K
- Earning Date
- NA 09-18-2024
- LPCN 11-07-2024
- Dividend Yield
- NA N/A
- LPCN N/A
- EPS Growth
- NA N/A
- LPCN N/A
- EPS
- NA N/A
- LPCN N/A
- Revenue
- NA $6,991,446.00
- LPCN $7,922,926.00
- Revenue This Year
- NA N/A
- LPCN N/A
- Revenue Next Year
- NA N/A
- LPCN N/A
- P/E Ratio
- NA N/A
- LPCN N/A
- Revenue Growth
- NA N/A
- LPCN N/A
- 52 Week Low
- NA $2.75
- LPCN $2.44
- 52 Week High
- NA $47.50
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- NA 52.67
- LPCN 50.88
- Support Level
- NA $6.67
- LPCN $4.70
- Resistance Level
- NA $10.42
- LPCN $5.28
- Average True Range (ATR)
- NA 1.94
- LPCN 0.32
- MACD
- NA -0.18
- LPCN 0.04
- Stochastic Oscillator
- NA 29.07
- LPCN 69.53
About NA Nano Labs Ltd
Nano Labs Ltd operates as a fabless IC design company and product solution provider in China. It engages in the development of HTC chips, HPC chips, distributed computing and storage solutions, smart-NICs, vision computing chips, and distributed rendering. Its products comprise Cuckoo 1.0 Chip, Cuckoo 2.0 Chip, and Darkbird 1.0 Chip. Majority of the company revenue comes from China.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.